Table 2.
Decreases in T-cell subsets and platelets.
| Bendamustine Dose | 70 mg/m2 | 90 mg/m2 | Total |
|---|---|---|---|
| No. of patients | 6 | 6 | 12 |
| Baseline CD4+ values (cells/mm3) | |||
| Median | 390 | 321 | 360 |
| Range | 73–5390 | 126–3792 | 73–5390 |
| Nadir CD4+ T-cells (% of baseline) | |||
| Median | 32% | 13% | 19% |
| Range | 22–56% | 1–29% | 1–56% |
| Recovery of CD4+ T-cells (% of baseline) | |||
| Median | 97% | 58% | 70% |
| Range | 11–274% | 71–140 | 11–274% |
| Baseline CD8 values (cells/mm3) | |||
| Median | 314 | 143 | 214 |
| Range | 77–4869 | 78–1795 | 77–4869 |
| Nadir CD8+ T-cells (% of baseline) | |||
| Median | 72% | 12% | 30% |
| Range | 1–140% | 4–41% | 1–140% |
| Recovery of CD8+ T-cells (% of baseline) | |||
| Median | 235% | 79% | 114% |
| Range | 14–529% | 32–148% | 14–529% |
| Decrease in platelets (nadir, absolute numbers, per nL) | |||
| Median | 18 | 25 | 25 |
| Range | 1–50 | 11–90 | 1–90 |
| Decrease in platelets (nadir, % of baseline) | |||
| No. of patients | 31% | 49% | 46% |
| % | 3–83% | 14–97% | 3–97% |